key: cord-0848390-3e3o9skp
authors: Kobayashi, Takashi
title: Editorial Comment from Dr Kobayashi to Effect of active anticancer therapy on serologic response to SARS‐CoV‐2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma
date: 2022-04-27
journal: Int J Urol
DOI: 10.1111/iju.14919
sha: ff71b7750daa55c1f9244583ad9f16e6cfa7e5d4
doc_id: 848390
cord_uid: 3e3o9skp

nan

In this issue of International Journal of Urology, Togashi et al. 1 reported the efficacy of vaccination for SARS-CoV-2 with BNT162b2 in patients with urothelial cancer (UC) and renal cell cancer (RCC) by evaluating post-vaccination seropositivity. The study demonstrated that humoral response, defined as an anti-SARS-CoV-2 IgG level ≥15 U/mL according to the manufacturer's data, was ≥90% among these patients. Although high, this proportion is considerably lower than the 99% to 100% found in control groups. 1-3 Indeed, the post-vaccination seropositivity in UC and RCC patients altogether was 91.8% (78 of 85), which was significantly lower than that in the control groups (P = 0.0415, Fisher's exact test).

It seems to be at least partly attributed to the significant difference in age between control group and the patients, as is often the case in such studies. 2 It should be also noted that the present study evaluated seropositivity after the second dose of BNT162b2. A previous report demonstrated that antibody levels increased significantly after the third booster dose, irrespective of active anticancer therapy being ongoing or not. 4 The authors may be able to evaluate antibody levels in their patients and controls after the booster doses.

As the authors also mentioned, there are a lot more to be answered in the future studies. How long will the antibody titers once established be maintained? Does tumor burden or anticancer therapy affect it? These data will be important when considering the optimal intervals for booster doses in patients on cancer treatment. Does tumor burden, metastatic site, or modality and intensity of anticancer therapy affect the susceptibilities to vaccine side effect, virus infection, aggravation, or mortality? Does vaccination itself affect treatment response, adverse treatment events, and prognosis of cancer patients? Considering that systemic immunological condition may substantially affect both SARS-CoV-2 vaccination and treatment outcome of UC/RCC patients and vice versa, 5 clinical significance of SARS-CoV-2 vaccination in cancer patients should be further studied.

Despite these unanswered questions, the authors should be congratulated for their timely report on the efficacy of SARS-CoV-2 vaccine in Japanese patients with UC or RCC. Further reports will be warranted in the future. 

Effect of active anticancer therapy on serologic response to SARS-CoV-2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma

Impaired seroconversion after SARS-CoV-2 mRNA vaccines in patients with solid tumours receiving anticancer treatment

Safety and immunogenicity of the COVID-19 vaccine BNT162b2 in patients undergoing chemotherapy for solid cancer

Assessment of response to a third dose of the SARS-CoV-2 BNT162b2 mRNA vaccine in patients with solid tumors undergoing active treatment

Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR

None declared.